Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer

• Status: Completed
• Trial end date: 2016-09-08
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to quantitatively assess the average amount of physical activity that patients are capable to perform while receiving regorafenib for the treatment of metastatic colorectal cancer. The assessment of this reference value, measured by CE (Conformité Européene)-certified pedometer and international physical activity questionnaire, will allow an estimation on the feasible amount of physical activity for patients in this therapeutic setting.

This study is available for patients who are included in the global non-interventional study CORRELATE (Safety and efficacy of regorafenib in metastatic colorectal cancer patients; NCT01843400) in Austria.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib.

• Patients enrolled in NIS CORRELATE in Austria

• Signed patient informed consent for local OS

Exclusion Criteria:

• Subjects unwilling to complete all questionnaires involved in the local OS

• Subjects unwilling to wear the pedometer